Sept 25 (Reuters) - Prometic Life Sciences Inc
* Prometic receives FDA clearance of its IND to initiate pivotal PBI-4050 phase 2/3 trial in patients with idiopathic pulmonary fibrosis
* Prometic Life Sciences Inc - Prometic plans to supplement IND with a protocol for a study of PBI-4050 monotherapy in IPF patients in October 2017
* Prometic Life Sciences Inc - U.S. IND to be followed by clinical trial applications in Canada, Europe, Australia and Japan throughout Q4 2017
* Prometic Life Sciences- Phase 3 stage would randomize an additional up to 450 subjects to receive nintedanib plus either placebo or chosen PBI-4050 dose Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.